Celldex Therapeutics new Trading Buy in STI Medical Profits Portfolio

By Joe Duarte • October 26, 2015

[from today’s edition of Smart Tech 50 Weekly Movers]

Celldex Therapeutics (CLDX) is almost an EBIS stock. The company is working on a vaccine for aggressive brain cancers. It has plenty of money on its balance sheet but is high risk and has not been able to make money consistently. In this market, it may be worth exploring on a trading basis with a buy limit of $14 and stop loss at $10.

Stock Talk

Comments

Comments Guidelines

Add New Comments

You must be logged in to post to Stock Talk OR create an account

About The Author

Joe Duarte

Bio | Archive

Dr. Joe Duarte is Chief Investment Strategist and Editor of Profit Catalyst Alert and Weekly Cash Machine. He has been a professional investor and independent analyst since 1990. He is a former Registered Investment Advisor and author of the Bestselling "Options Trading for Dummies," now in its 4th edition and several other books including "Market Timing for Dummies" and "Successful Biotech Investing". Although Joe's favorite areas of the market are technology and healthcare, he is a versatile investor who enjoys finding that hidden gem stock before the crowd, no matter what the sector. He is an original CNBC Market Maven, and is visible regularly on Stockcharts.TV. He has published articles on Marketwatch.com and has been widely quoted in the major media including The Wall Street Journal and Barron’s magazine.